《大行報告》匯豐研究上調復星醫藥(02196.HK)目標價至46元 評級「買入」
匯豐環球研究發表報告,分別下調復星醫藥(02196.HK)今明兩年收入預測各12%,及調低經營利潤預測各13%,以反映帶量採購對主要藥品的影響;不過今明兩年純利預測則分別上調1%及6%,主因國藥(01099.HK)的增長前景改善。
該行預期,復星醫藥2020至2023年的收入年均複合增長率為15%,主要受到中藥、健康護理服務及醫療器材業務推動,相信集團新藥的推出,足以抵銷藥品帶量採購的影響。至於集團2020至2023年的經營利潤年均複合增長率則料為19%。
匯豐研究上調復星醫藥股份目標價,由37.8元升至46元,評級維持「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.